What is the efficacy of cabozantinib (Cabometyx) in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

In December 2017, the FDA approved cabozantinib for first-line treatment of advanced RCC. Approval was based on findings from the CABOSUN trial, a randomized, open-label phase II multicenter study. The study enrolled 157 patients with intermediate- and poor-risk previously untreated RCC. Patients received either cabozantinib or sunitinib daily (4 weeks on treatment followed by 2 weeks off) until disease progression or unacceptable toxicity. Estimated median progression-free survival for patients taking cabozantinib was 8.6 months compared with 5.3 months for patients taking sunitinib. [53]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!